Abstract:| https://dx.doi.org/10.21037/hbsn-21-392 Up to know, product information for COVID-19 mRNA vaccines do not include their use in patients receiving immunosuppressive medication, since they were not included in trials (1) . For the BNT162b2 mRNA vaccine, one case of otherwise totally asymptomatic elevations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (GGT) serum concentrations in a liver transplant recipient has been reported after the first injection (2). In the present retrospective study, we present safety outcomes of COVID-19 vaccinations in 56 liver transplant patients from two Chinese centers vaccinated with the domestic PiCoVacc, BBIBP-CorV and ZF2001 vaccines. Thirty vaccinated physicians from the Hepatopancreatobiliary Center of Beijing Tsinghua Changgung Hospital served as control, from which 1 participant received an Ad5-nCoV vaccine. The study deadline was 2021-10-31. The observation period for adverse reactions, such as muscle pain and fatigue was 1 week, while for laboratory examinations such as liver function the follow-up period was 1 month. PiCoVacc and BBIBP-CorV are both inactivated COVID-19 virus vaccines with a two-dose schedule and a spacing of 3 to 4 weeks, while ZF2001 is a recombinant tandem-repeat dimeric receptor-binding domain (RBD)based protein subunit vaccine with an application of three doses over a period of 2 months. Ad5-nCoV is a viral vector vaccine applied as a single injection. Table 1 shows the basic characteristics of the 86 participants. Adverse reactions in the liver transplant and control groups were fatigue (4, 7.1% vs. 1, 3.3%), local pain (9, 16.1% vs. 6, 20.0%), cough (1, 1.8% vs. 0), rhinorrhea (1, 1.8% vs. 0) and drowsiness (0 vs. 4, 13.3%), respectively. All adverse reactions were mild. Fifty-four participants had normal liver function tests within 1 month before and after vaccination. A 37-year-old patient, 70 months after transplantation due to a primary liver cancer who was receiving an antirejection regimen of sirolimus + mycophenolate mofetil (MMF), had liver enzyme values of ALT 72.0 U/L, AST 37.6 U/L, total bilirubin (TBIL) 13.7 μmol/L, ALP 80.0 U/L and GGT 58.3 U/L before and ALT 68.3 U/L, AST 37.7 U/L, TBIL 11.0 μmol/L, ALP 96.0 U/L and GGT 62.2 U/L after vaccination. The condition was considered to be related to the graft fatty liver and the liver function changes were not significant before and after vaccination. The second case was a 46-year-old patient with hepatic alveolar echinococcosis 30.7 months after transplantation and an anti-rejection regimen of tacrolimus + MMF. Liver enzyme values were ALT 22 U/L, AST 29 U/L, TBIL 12.4 μmol/L, ALP 134 U/L, GGT 44 U/L before and ALT 19 U/L, AST 25 U/L, TBIL 11 μmol/L, ALP 106 U/L and GGT 41 U/L after vaccination. The patient underwent a choledochojejunostomy, because of a narrow biliary anastomosis. Since there was no stenosis after the choledochojejunostomy, this abnormal ALP may be related to the state of bilioenteroanastomosis. Two of the vaccines in the present study were inactivated viruses, which are only recommended for solid organ transplant recipients after careful risk benefit assessment, Letter to the Editor

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine

Clinical application of COVID-19 vaccine in liver transplant recipients

Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients

Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre

High vaccination coverage and infection rate result in a robust SARS‐CoV‐2‐specific immunity in the majority of liver cirrhosis and transplant patients: A single‐center cross‐sectional study

Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines

COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses

Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination

A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients

Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients

Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico

Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients

Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis

Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis

Extending the Dosing Interval of COVID-19 Vaccination Leads to Higher Rates of Seroconversion in People Living with HIV.

Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Safety Analysis of COVID-19 Vaccines in Liver Transplant Recipients: a Two-Center Study.

Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need

Predictors of Specific Cellular Immunity Response in Kidney Transplant Recipients after Administration of SARS-CoV-2 Inactivated Vaccine

SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients